By network meta- analysis , sildenafil seems to be the most efficiency with a slightly higher rate of treatment-emergent adverse events ( TEATs ) , whereas tadalafil had the lowest TEATs .
Compared with placebo , PDE5-Is manifested significantly improved treatment outcomes .
Overall , regular regimen demonstrated statistically pronounced better potency than on-dem and .
Phosphodiesterase type-5 inhibitors ( PDE5-Is ) have been recommended as first line therapy for erectile dysfunction for patients received nerve-sparing radical prostatectomy for prostate cancer .
We examed the efficiency of PDE5-Is and considered the optimal application .
An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries.
OBJECTIVE To examine the preference for 2 dosing regimens ( on dem and or 3 times/week ) for tadalafil , a phosphodiesterase 5 inhibitor with a duration of effectiveness up to 36 hours in men with erectile dysfunction ( ED ) . DESIGN AND METHODS SURE is a 14 European country , multicenter , crossover , and open-label study . Men with ED ( N=4262 ) were r and omized to tadalafil 20 mg treatment on dem and ( maximum one dose per day and before sexual activity ) or 3 times/week for 5 - 6 weeks . After a 1-week washout period , patients were crossed over to the alternate regimen for 5 - 6 weeks . The patient 's response to a treatment preference question ( TPQ ) was used to determine the preferred treatment regimen . RESULTS The mean age of the r and omized patients was 55 years and 85.2 % reported a history of ED for one year or greater . Overall , the responses of 3861 men to the TPQ assessment showed that 57.8 % preferred the on-dem and regimen and 42.2 % preferred the 3 times/week dosing . Both regimens were efficacious and well tolerated . CONCLUSIONS In this study , while 57.8 % of men preferred the on-dem and regimen of tadalafil 20 mg , a substantial number ( 42.2 % ) preferred the 3 times/week treatment . The two regimens provide additional treatment options by giving men with erectile dysfunction unique flexibility in dosing with tadalafil
By network meta- analysis , sildenafil seems to be the most efficiency with a slightly higher rate of treatment-emergent adverse events ( TEATs ) , whereas tadalafil had the lowest TEATs .
Compared with placebo , PDE5-Is manifested significantly improved treatment outcomes .
Overall , regular regimen demonstrated statistically pronounced better potency than on-dem and .
Phosphodiesterase type-5 inhibitors ( PDE5-Is ) have been recommended as first line therapy for erectile dysfunction for patients received nerve-sparing radical prostatectomy for prostate cancer .
We examed the efficiency of PDE5-Is and considered the optimal application .